[1]唐小龙,杨丽霞,缪延栋,等.基于网络药理学探讨“兰州方”治疗急性髓系白血病的机制[J].西部中医药,2022,35(10):35-41.[doi:10.12174/j.issn.2096-9600.2022.10.08]
　TANG Xiaolong,YANG Lixia,MIU Yandong,et al.The Effects of "Lanzhou Prescription" in the Treatment of Acute Myelogenous Leukemia Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):35-41.[doi:10.12174/j.issn.2096-9600.2022.10.08]
点击复制

基于网络药理学探讨“兰州方”治疗急性髓系白血病的机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年10期
页码:
35-41
栏目:
出版日期:
2022-10-15

文章信息/Info

Title:
The Effects of "Lanzhou Prescription" in the Treatment of Acute Myelogenous Leukemia Based on Network Pharmacology
作者:
唐小龙1,2, 杨丽霞3, 缪延栋2, 哈武华2, 米登海2,3
1.川北医学院附属医院，四川 南充 637000
2.兰州大学第一临床医学院
3.甘肃省中医药研究院
Author(s):
TANG Xiaolong1,2, YANG Lixia3, MIU Yandong2, HA Wuhua2, MI Denghai2,3
1.Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China
2.The First Clinical Medical College of Lanzhou University
3.Gansu Provincial Academy of Chinese Medicine
关键词:
白血病; 髓系; 急性; 兰州方; 网络药理学; 分子对接
Keywords:
acute;  myelogenous leukemia; prescription; network pharmacology; molecular docking
分类号:
R733.71
DOI:
10.12174/j.issn.2096-9600.2022.10.08
文献标志码:
A
摘要:
目的基于网络药理学探讨“兰州方”治疗急性髓系白血病（acute myelogenous leukemia，AML）的药理机制。 方法通过中药系统药理学与分析平台（traditional Chinese medicine systems phar-macology database，TCMSP）收集“兰州方”的活性成分及对应作用靶点。从Disgenet、Drugbank、NCBI、OMIM、Pharmgkb和TTD疾病数据库中收集AML的相关靶点。使用Cytoscape软件建立“兰州方”治疗AML的有效成分及对应靶点的网络，探寻药物主要活性成分，并利用CytoNCA和CytoHubba插件寻找治疗作用的核心基因。通过基因本体（gene ontology，GO）和京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）分析“兰州方”治疗AML起作用的主要功能和通路，通过分子对接验证化合物与靶蛋白的亲和性。 结果“兰州方”中共有139种与AML相关的有效化合物。6个疾病数据库中共收集到348个AML疾病相关基因，其中有39个“兰州方”作用于AML的靶基因。“兰州方”中Quercetin、Luteolin、Kaempferol、Naringenin、Diosgenin可能是治疗AML的主要活性成分。治疗作用影响的核心基因有MAPK3、STAT3、TP53、VEGFA、HIF1A、IL1B、CXCL8和PTGS2。GO分析发现“兰州方”治疗AML的基因功能主要富集在血管生成、活性氧代谢过程、对有毒物质的反应及代谢过程等。KEGG分析发现主要通路富集在铂类药物抵抗、癌症中的miRNA、PI3K-Akt通路、HIF-1通路、癌症中的转录失调、VEGF信号通路、NF-kappa B信号通路等。分子对接结果显示“兰州方”中多种化合物与疾病相关靶点PTGS2具有良好的亲和性。 结论“兰州方”通过“多种药物，多个靶点”的模式治疗AML。
Abstract:
ObjectiveTo discuss the pharmacological mechanism of "Lanzhou prescription" in the treatment of AML based on network pharmacology. MethodsActive ingredients and the corresponding targets of "Lanzhou prescription" were collected via TCMSP, the related targets of AML were gathered from Disgenet, Drugbank, NCBI, OMIM, pharmgkb and TTD disease databases, the effective constituents of "Lanzhou prescription" in treating AML and the network of the corresponding targets were constructed by using cytoscape software, to investigate the main active ingredients of the medicine, the core genes of therapeutic effects were surveyed by applying CytoNCA and CyteHubba plug-in. The main function and pathways of "Lanzhou prescription" in the treatment of AML were analyzed by GO and KEGG, the affinity of the compound to the target protein was verified by molecular docking. ResultsThere were 139 effective constituents contained in"Lanzhou prescription", closely related to AML. From six disease databases, 348 AML-associated genes were collected, among them, 39 target genes acting on AML were found in "Lanzhou prescription". Quercetin, Luteolin, and Kaempferol, Naringenin tog-ether with Diosgenin might be the main effective constituents of treating AML. The core genes affected by therapeutic effects were MAPK3, STAT3, TP53, VEGFA, HIF1A, IL1B, CXCL8 and PTGS2. GO analysis showed that gene functions of "Lanzhou prescription" in treating AML were enriched in angiogenesis, metabolic process of reactive oxygen, the response to toxic substances and its metabolic process. KEGG analysis revealed that the pathways were enriched in platinum drug resistance, miRNA, PI3K-AKt pathway and HIF-1 pathway, transcription disorder, VEGF signaling pathway and NF-kappa B signaling pathway. The results of molecular docking displayed that many compounds of "Lanzhou prescription" had the good affinity with disease-related targets PTGS2. Conclusion"Lanzhou prescription" could treat AML through the mode of "many medicines and targets".

相似文献/References:

[1]贾澜,陈瑞明.陈文选老中医治疗儿童白血病临证经验心悟[J].西部中医药,2013,26(08):34.
　JIA Lan,CHEN Ruiming.Veteran TCM Doctor CHEN Wenxuan′s Experience of Treating Children with Leukemia[J].Western Journal of Traditional Chinese Medicine,2013,26(10):34.
[2]祁元刚.裴正学教授治疗白血病经验小结[J].西部中医药,2015,28(06):39.[doi:2015/6/16 0:00:00]
[3]夏小军,段赟.中医药治疗急性白血病的思路与方法[J].西部中医药,2016,29(04):41.
　XIA Xiaojun,DUAN Yun.The Method and Thinking of TCM in Treating Acute Leukemia[J].Western Journal of Traditional Chinese Medicine,2016,29(10):41.
[4]徐晓敏,谢 珺,张琳敏.基于健康信念的照护策略对白血病化疗患者自我管理能力的影响[J].西部中医药,2018,31(09):128.
　XU Xiaomin,XIE Jun,ZHANG Linmin.Effects of Nursing Strategy on Self-management Ability of Leukemia Patients Who Underwent Chemotherapy Based on Health Beliefs[J].Western Journal of Traditional Chinese Medicine,2018,31(10):128.
[5]夏小军,段赟.中医药治疗慢性髓系白血病的思路与方法[J].西部中医药,2018,31(02):35.
　XIA Xiaojun,DUAN Yun.The Thinking and Method of TCM in Treating Chronic Myeloid Leukemia[J].Western Journal of Traditional Chinese Medicine,2018,31(10):35.
[6]王燕,谢亲建,马弢业,等.白刺果作用于白血病NB4细胞的机制研究[J].西部中医药,2021,34(04):28.[doi:10.12174/j.issn.2096-9600.2021.04.07]
　WANG Yan,XIE Qinjian,MA Taoye,et al.Study on the Mechanism of Baiciguo Acting on Leukemia NB4 Cells[J].Western Journal of Traditional Chinese Medicine,2021,34(10):28.[doi:10.12174/j.issn.2096-9600.2021.04.07]
[7]夏小军,段赟,包晓玲,等.回生胶囊配合化疗治疗急性髓系白血病189例[J].西部中医药,2019,32(06):95.
　XIA Xiaojun,DUAN Yun,BAO Xiaoling,et al.Huisheng Capsules Combined with Chemotherapy in Treating 189 Patients Suffering Acute Myeloid Leukemia[J].Western Journal of Traditional Chinese Medicine,2019,32(10):95.

备注/Memo

备注/Memo:
唐小龙（1988—），男，博士学位，医师。研究方向：肿瘤疾病的中西医结合诊治及研究。甘肃省科技创新基地和人才计划项目（20JR10RA432）。
更新日期/Last Update: 2022-10-15